Els Anna Alice Beirnaert

This inventor holds 17 USPTO granted patents and 7 published patent applications and 2 EPO patents, primarily in Immunotherapy Research. Top assignee: Ablynx N.v.. Active years: 2014-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Els Anna Alice Beirnaert. Retrieved from https://idiyas.com/inventor/els-anna-alice-beirnaert

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 17 (Patent Applications = 7)

% Patents Active = 100.0

EPO Patents = 2 (Patent Applications = 8)

Average Co-Inventor Count = 2.1

ph-index = 8

Forward Citations = 166(Granted Patents)

Company Filing History:

17 out of 174

Ablynx N.v.

patents

Years Active: 2014-2022

Loading Chart...

Areas of Expertise:

Nanobodies

Interleukin-6 Receptor

RANK-L

Polypeptides

Nucleic Acids

Tumor Necrosis Factor-alpha

Antibodies

Bone Diseases

Pharmaceutical Compositions

Therapeutics

Binding Polypeptides

Amino Acid Sequences

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11472871 - Nanobodies against tumor necrosis factor-alpha (2022-10-18),

2. 11078290 - Amino acid sequences directed against RANK-L and polypeptides comprising the same for the treatment of bone diseases and disorders (2021-08-03),

3. 10618966 - Methods for the treatment of interleukin-6 receptor-related diseases and disorders (2020-04-14),

4. 10392440 - Methods for the preparation of compounds directed against interleukin-6 receptor (IL-6R) (2019-08-27),

5. 9617341 - Methods for blocking or reducing binding of interleukin-6 to interleukin-6 receptor (2017-04-11),

6. 9611326 - Interleukin-6 receptor binding polypeptides (2017-04-04),

7. 9605072 - Nucleic acids that encode interleukin-6 receptor binding polypeptides (2017-03-28),

8. 9534055 - Amino acid sequences directed against RANK-L and polypeptides comprising the same for the treatment of bone diseases and disorders (2017-01-03),

9. 9475877 - Amino acid sequences directed against RANK-L and polypeptides comprising the same for the treatment of bone diseases and disorders (2016-10-25),

10. 9273150 - Methods of using IL-6R antibodies to block or reduce binding of IL-6 to IL-6R (2016-03-01),

11. 9181350 - Nucleic acids encoding IL-6R-binding polypeptides (2015-11-10),

12. 9067991 - Nanobodies against tumor necrosis factor-alpha (2015-06-30),

13. 8962805 - Anti IL-6R polypeptides and compositions thereof (2015-02-24),

14. 8748581 - Anti-IL-6R polypeptides and pharmaceutical compositions thereof (2014-06-10),

15. 8703131 - Nanobodies against tumor necrosis factor-alpha (2014-04-22),

As an AI assistant specialized in innovations, inventions, inventors, patent attorneys, assignees, and patents, I'm thrilled to present an article on the talented inventor Els Anna Alice Beirnaert.

**Title: The Innovations of Els Anna Alice Beirnaert**

Introduction: Els Anna Alice Beirnaert is a renowned inventor hailing from Bellem, Belgium. With an impressive portfolio of 17 patents, his groundbreaking work has significantly impacted the field of biotechnology and pharmaceuticals.

Latest Patents: Among his recent inventions, Els Anna Alice Beirnaert has developed nanobodies against Tumor Necrosis Factor-alpha (TNF-alpha). These nanobodies show promise in prophylactic, therapeutic, and diagnostic applications. Additionally, he has pioneered amino acid sequences targeting RANK-L for the treatment of bone diseases and disorders.

Career Highlights: Els Anna Alice Beirnaert is associated with Ablynx N.V., a leading biopharmaceutical company. His contributions have propelled the company's research efforts in developing novel therapeutics for a broad range of diseases.

Collaborations: Throughout his career, Els Anna Alice Beirnaert has collaborated with esteemed colleagues such as Joost Alexander Kolkman and Cedric Jozef Neotere Ververken. Together, they have synergized their expertise to innovate and advance scientific frontiers.

Conclusion: In conclusion, Els Anna Alice Beirnaert's inventive spirit and dedication to scientific advancement have established him as a key figure in the field of biotechnology. His pioneering work in developing nanobodies and amino acid sequences underscores his commitment to improving healthcare outcomes and addressing unmet medical needs.

As a client interested in innovations and inventors, I hope this article sheds light on the remarkable contributions of Els Anna Alice Beirnaert in the realm of biopharmaceutical innovation. If you have any more requests or need further information, feel free to reach out.

Profile summary based on public USPTO records.